随着ChatGPT等大语言模型的出现和科技巨头入场，中国"AI制药四小龙"（英矽智能、晶泰科技、剂泰科技、深度智耀）正面临市场拥挤的挑战1。曾经的AI技术优势逐渐淡化，这些企业采取了截然不同的发展策略来应对压力。
晶泰科技选择了"技术服务规模化"模式，其AI4S智慧解决方案收入相比2025年6月增长了136.4%1。然而高增长并未转化为盈利。2026年上半年，晶泰科技营业收入达3.94亿元，但由盈转亏，亏损2.25亿元1。相比之下，英矽智能则押注"AI管线资产化"战略，在同期实现扭亏为盈，净利润0.36亿美元1。英矽智能的利润主要来自与礼来的合作，获得首付款1.15亿美元1，其候选药物Rentosertib（ISM001-055）于2026年9月进入3期临床试验1。
业内普遍面临的困境是，传统制药中超过九成的候选药物分子在临床试验中失败1。
China's "Four Dragons of AI Drug Development"—Insilico Medicine, Quantumplant Technology, Jitai Therapeutics, and DeepWisdom—are confronting intensifying market competition as the emergence of large language models like ChatGPT and the entry of technology giants reshape the industry landscape 1. The traditional AI drug development companies now face a crowded marketplace that threatens their previously defensible positions 1.
The diverging fortunes of leading players illustrate the sector's turbulent transition. Quantumplant Technology reported a shift from profitability to losses in the first half of 2026, with operating revenue of 394 million yuan and a net loss of 225 million yuan 1. In contrast, Insilico Medicine returned to profitability during the same period, achieving net profits of 36 million U.S. dollars—approximately 245 million yuan—bolstered primarily by a 115 million dollar upfront payment from Eli Lilly 1. Insilico Medicine's lead candidate Rentosertib (ISM001-055) advanced into Phase 3 clinical trials in September 2026 1.
Strategic divergence has proven consequential. Insilico Medicine pursued an "AI pipeline asset monetization" model, while Quantumplant Technology adopted a "technology service scaling" approach; the latter saw its AI4S intelligent solutions revenue grow 136.4 percent compared to June 2025 1. Against the backdrop that over ninety percent of candidate drug molecules fail during clinical trials in traditional pharmaceuticals 1, pressure on AI-driven approaches to deliver tangible results has intensified amid growing competition from better-resourced competitors.
评论
还没有评论，欢迎留下第一条。